{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:55:02Z","timestamp":1766159702222,"version":"3.41.2"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Xuebijing (XBJ) is a traditional Chinese medicine widely used in China for managing sepsis, systemic inflammatory response syndrome, and multiple organ dysfunction secondary to severe infections. This study aimed to assess the therapeutic efficacy and safety of XBJ as an adjuvant treatment for <jats:italic>Acinetobacter baumannii<\/jats:italic> (<jats:italic>A. baumannii<\/jats:italic>) infections through meta-analysis, and to explore its potential mechanisms via integrated pharmacological approaches.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A systematic search was conducted across multiple databases for randomized controlled trials (RCTs) evaluating XBJ in <jats:italic>A. baumannii<\/jats:italic> infections up to 9 February 2025. Meta-analyses were conducted to synthesize clinical outcomes, and evidence certainty was assessed using the GRADE framework. Network pharmacology, molecular docking, and molecular dynamics simulations were used to evaluate the interactions between active ingredients of XBJ and protein targets in <jats:italic>A. baumannii<\/jats:italic> infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 11 RCTs involving 1,035 patients met the inclusion criteria. Meta-analysis demonstrated that XBJ significantly improved clinical outcomes, with a higher overall effective rate (RR = 1.20, 95% CI: 1.13\u20131.27, <jats:italic>P<\/jats:italic> &amp;lt; 0.01) and enhanced bacterial clearance (RR = 1.44, 95% CI: 1.23\u20131.68, <jats:italic>P<\/jats:italic> &amp;lt; 0.01) compared to conventional treatment alone. Additionally, XBJ treatment was associated with marked reductions in inflammatory markers, including C-reactive protein (CRP) (SMD = \u22122.12), procalcitonin (PCT) (SMD = \u22122.28), and white blood cell (WBC) count (SMD = \u22121.00) (all <jats:italic>P<\/jats:italic> &amp;lt; 0.01). Notably, no serious adverse drug events were reported. Mechanistic investigations identified three active ingredients of XBJ including scutellarin, salvianolic acid C, and isosalvianolic acid C, as potential modulators of MMP9 and TLR4, suggesting the role of XBJ in attenuating inflammatory responses and improving infection outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>XBJ appears effective and safe as an adjuvant therapy for <jats:italic>A. baumannii<\/jats:italic> infections, but further high-quality RCTs are warranted to validate these findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>, identifier CRD42023486389.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1598359","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T05:29:56Z","timestamp":1747978196000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic efficacy and mechanisms of Xuebijing in Acinetobacter baumannii infection based on meta-analysis and integrated pharmacology approaches"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiaqi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boying","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiyu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/antibiotics9030119","article-title":"Insights into acinetobacter baumannii: a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen","volume":"9","author":"Ayoub Moubareck","year":"2020","journal-title":"Antibiot. (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3969\/j.issn.1006-6233.2017.04.038","article-title":"Efficacy of xuebijing in the treatment of severe pneumonia caused by acinetobacter baumannii resistant to bauman","volume":"23","author":"Bai","year":"2017","journal-title":"Hebei Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid. Based Ment. Health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1196774","DOI":"10.3389\/fmicb.2023.1196774","article-title":"Acinetobacter baumannii in the critically ill: complex infections get complicated","volume":"14","author":"Cavallo","year":"2023","journal-title":"Front. Microbiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"115189","DOI":"10.1016\/j.biopha.2023.115189","article-title":"Comparative transcriptomics analysis of multidrug-resistant Acinetobacter baumannii in response to treatment with the terpenic compounds thymol and carvacrol","volume":"165","author":"Cirino","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"W357","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jhin.2024.04.013","article-title":"Risk factors for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii infection of patients admitted in intensive care unit: a systematic review and meta-analysis","volume":"149","author":"Diao","year":"2024","journal-title":"J. Hosp. Infect."},{"key":"B8","first-page":"427","article-title":"Clinical study on the combined use of XueBiJing injection and intravenous administration of ceftazidime\/avibactam in the treatment of patients with severe pneumonia caused by extensively drug-resistant acinetobacter baumannii","volume":"28","author":"Dong","year":"2019","journal-title":"Mod. Med. Imageology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3389\/fimmu.2017.00441","article-title":"The immune response against acinetobacter baumannii, an emerging pathogen in nosocomial infections","volume":"8","author":"Garcia-Patino","year":"2017","journal-title":"Front. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.21037\/apm-20-1478","article-title":"Xuebijing injection in the treatment of COVID-19: a retrospective case-control study","volume":"9","author":"Guo","year":"2020","journal-title":"Ann. Palliat. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10753-011-9393-6","article-title":"Antibacterial and anti-inflammatory activity of traditional Chinese herb pairs, Angelica sinensis and Sophora flavescens","volume":"35","author":"Han","year":"2012","journal-title":"Inflammation"},{"key":"B12","article-title":"Dmetar: companion R package for the guide 'doing meta-analysis in R","author":"Harrer","year":"2019","journal-title":"R. package version 0.1.0"},{"key":"B13","first-page":"31","article-title":"Study on the clinical effect of Xuebijing Injection combined with Tigefycline in the treatment of pulmonary infection of Acinetobacter Baumannii","volume":"26","author":"He","year":"2019","journal-title":"China Mod. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/pca.1284","article-title":"Identification of the major constituents in Xuebijing injection by HPLC-ESI-MS","volume":"22","author":"Huang","year":"2011","journal-title":"Phytochem. Anal."},{"key":"B15","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jep.2013.03.032","article-title":"Identification of NF-\u03baB Inhibitors in Xuebijing injection for sepsis treatment based on bioactivity-integrated UPLC-Q\/TOF","volume":"147","author":"Jiang","year":"2013","journal-title":"J. Ethnopharmacol."},{"key":"B16","article-title":"Cochrane Handbook for systematic reviews of interventions version 6.4","volume-title":"Cochrane","author":"Jpt","year":"2023"},{"key":"B17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13020-022-00587-7","article-title":"Efficacy and mechanisms of traditional Chinese medicine for COVID-19: a systematic review","volume":"17","author":"Kang","year":"2022","journal-title":"Chin. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/pathogens10030373","article-title":"Acinetobacter baumannii antibiotic resistance mechanisms","volume":"10","author":"Kyriakidis","year":"2021","journal-title":"Pathogens"},{"key":"B19","doi-asserted-by":"publisher","first-page":"563516","DOI":"10.3389\/fgene.2021.563516","article-title":"Proteomics landscape of host-pathogen interaction in acinetobacter baumannii infected mouse lung","volume":"12","author":"Li","year":"2021","journal-title":"Front. Genet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"341799","DOI":"10.1016\/j.aca.2023.341799","article-title":"An aggregation-induced emission sensor combined with UHPLC-Q-TOF\/MS for fast identification of anticoagulant active ingredients from traditional Chinese medicine","volume":"1279","author":"Li","year":"2023","journal-title":"Anal. Chim. Acta"},{"key":"B21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.14035\/j.cnki.hljyy.2019.01.008","article-title":"Clinical study on the combined treatment of pyelonephritis caused by acinetobacter baumannii infection with ceftriaxone sodium","volume":"32","author":"Liu","year":"2019","journal-title":"Heilongjiang Med. J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1001\/jamainternmed.2023.0780","article-title":"Effect of an herbal-based injection on 28-day mortality in patients with sepsis: the EXIT-SEP randomized clinical trial","volume":"183","author":"Liu","year":"2023","journal-title":"JAMA Intern Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"649390","DOI":"10.3389\/fmicb.2021.649390","article-title":"Paeoniflorin derivative in paeoniae radix aqueous extract suppresses alpha-toxin of Staphylococcus aureus","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Microbiol."},{"key":"B24","first-page":"048","article-title":"Clinical efficacy analysis of XueBiJing injection as adjunctive therapy for acinetobacter baumannii pulmonary infection","volume":"22","author":"Liu","year":"2020","journal-title":"China Health Vis."},{"key":"B25","first-page":"26","article-title":"Clinical study on the treatment of severe pneumonia caused by extensively drug-resistant acinetobacter baumannii with xuebijing injection combined with ceftazidime-avibactam sodium","volume":"4","author":"Ma","year":"2024","journal-title":"Med. Health"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.3866\/pku.whxb20090907","article-title":"Effects of the multi-target capability of Xuebijing and its inflammatory pharmacodynamic material basis","volume":"25","author":"Ma","year":"2009","journal-title":"Acta Physico-Chimica Sin."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.3969\/j.issn.1006-6233.2018.11.024","article-title":"Comparison of efficacy and safety of tegacycline combined with xuebijing and cefoperazone sulbactam in the treatment of carbapenem-resistant acinetobacter baumannii infection","volume":"24","author":"Ma","year":"2018","journal-title":"Hebei Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.12174\/j.issn.1004-6852.2020.07.29","article-title":"The effects of xuebijing injection and tigecyclineon carbapenem resistant acinetobacter baumannii infection","volume":"33","author":"Ma","year":"2020","journal-title":"West. J. Traditional Chin. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"6814","DOI":"10.3390\/ijms25136814","article-title":"Unveiling the secrets of acinetobacter baumannii: resistance, current treatments, and future innovations","volume":"25","author":"Marino","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1583773","DOI":"10.1155\/2022\/1583773","article-title":"Bibliometric analysis of network pharmacology in traditional Chinese medicine","volume":"2022","author":"Miao","year":"2022","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s10096-023-04668-9","article-title":"Risk factors for progression to bacteremia among patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia in the Intensive Care Unit","volume":"42","author":"Niu","year":"2023","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3969\/j.issn.1004-4337.2022.02.017","article-title":"Comparative effectiveness of tigecycline combined with XueBiJing and ceftazidime\/avibactam in the treatment of carbapenem-resistant and pan-drug-resistant acinetobacter baumannii infections","volume":"35","author":"Niu","year":"2022","journal-title":"J. Math. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3390\/antibiotics12030516","article-title":"Colistin resistance in acinetobacter baumannii: molecular mechanisms and epidemiology","volume":"12","author":"Novovic","year":"2023","journal-title":"Antibiot. (Basel)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B35","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3969\/j.issn.2095-0616.2021.16.021","article-title":"Clinical study of tigecycline, sulperazone and Xuebijing in the combined treatment of severe pneumonia caused by extensively drug-resistant acinetobacter baumannii","volume":"11","author":"Pang","year":"2021","journal-title":"China Med. Pharm."},{"key":"B36","doi-asserted-by":"publisher","first-page":"R127","DOI":"10.1186\/gb-2009-10-11-r127","article-title":"Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis","volume":"10","author":"Pankla","year":"2009","journal-title":"Genome Biol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3390\/antibiotics11121793","article-title":"Acinetobacter baumannii resistance to sulbactam\/durlobactam: a systematic review","volume":"11","author":"Principe","year":"2022","journal-title":"Antibiot. (Basel)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3390\/antibiotics13030261","article-title":"Current therapeutic approaches for multidrug-resistant and extensively drug-resistant acinetobacter baumannii infections","volume":"13","author":"Rafailidis","year":"2024","journal-title":"Antibiot. (Basel)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3390\/ph16091281","article-title":"An update on the therapeutic potential of antimicrobial peptides against acinetobacter baumannii infections","volume":"16","author":"Rangel","year":"2023","journal-title":"Pharm. (Basel)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e2451170","DOI":"10.1002\/eji.202451170","article-title":"Innate immune mechanisms promote human response to Acinetobacter baumannii infection","volume":"54","author":"Sabatini","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1053968","DOI":"10.3389\/fcimb.2023.1053968","article-title":"Deciphering the virulence factors, regulation, and immune response to Acinetobacter baumannii infection","volume":"13","author":"Shadan","year":"2023","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1332108","DOI":"10.3389\/fmicb.2024.1332108","article-title":"Acinetobacter baumannii: an evolving and cunning opponent","volume":"15","author":"Shi","year":"2024","journal-title":"Front. Microbiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1003658","DOI":"10.3389\/fphar.2023.1003658","article-title":"Traditional Chinese medicine for treatment of sepsis and related multi-organ injury","volume":"14","author":"Song","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e735","DOI":"10.1097\/CCM.0000000000003842","article-title":"XueBiJing injection versus placebo for critically ill patients with severe community-acquired pneumonia: a randomized controlled trial","volume":"47","author":"Song","year":"2019","journal-title":"Crit. Care Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1141490","DOI":"10.3389\/fcimb.2023.1141490","article-title":"Resistance mechanisms of tigecycline in Acinetobacter baumannii","volume":"13","author":"Sun","year":"2023","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"16921","DOI":"10.1038\/s41598-017-17170-y","article-title":"Chemical profiling and quantification of XueBiJing injection, a systematic quality control strategy using UHPLC-Q Exactive hybrid quadrupole-orbitrap high-resolution mass spectrometry","volume":"7","author":"Sun","year":"2017","journal-title":"Sci. Rep."},{"key":"B48","doi-asserted-by":"publisher","first-page":"111367","DOI":"10.1016\/j.isci.2024.111367","article-title":"Carbapenem-resistant Acinetobacter baumannii raises global alarm for new antibiotic regimens","volume":"27","author":"Thacharodi","year":"2024","journal-title":"iScience"},{"key":"B49","doi-asserted-by":"publisher","first-page":"6879278","DOI":"10.1155\/2021\/6879278","article-title":"Scientific evidence of xuebijing injection in the treatment of sepsis","volume":"2021","author":"Tian","year":"2021","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"870101","DOI":"10.3389\/fmicb.2022.870101","article-title":"Acinetobacter baumannii secretes a bioactive lipid that triggers inflammatory signaling and cell death","volume":"13","author":"Tiku","year":"2022","journal-title":"Front. Microbiol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"B53","doi-asserted-by":"publisher","first-page":"116208","DOI":"10.1016\/j.jep.2023.116208","article-title":"Clinical efficacy and safety of compound Congrong Yizhi Capsules on Alzheimer's disease in mainland China: a systematic review with trial sequential analysis and GRADE assessment","volume":"309","author":"Wang","year":"2023","journal-title":"J. Ethnopharmacol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13063-019-3204-z","article-title":"Efficacy and safety of Xuebijing injection and its influence on immunomodulation in acute exacerbations of chronic obstructive pulmonary disease: study protocol for a randomized controlled trial","volume":"20","author":"Xie","year":"2019","journal-title":"Trials"},{"key":"B55","doi-asserted-by":"publisher","first-page":"949254","DOI":"10.1155\/2014\/949254","article-title":"Treatment effects of xuebijing injection in severe septic patients with disseminated intravascular coagulation","volume":"2014","author":"Yin","year":"2014","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.jpha.2022.01.001","article-title":"Novel assays for quality evaluation of XueBiJing: quality variability of a Chinese herbal injection for sepsis management","volume":"12","author":"Yu","year":"2022","journal-title":"J. Pharm. Anal."},{"key":"B57","doi-asserted-by":"publisher","first-page":"8059","DOI":"10.16281\/j.cnki.jocml.2017.41.095","article-title":"Exploring the therapeutic effectiveness of XueBiJing in the treatment of acinetobacter baumannii-induced pyelonephritis","volume":"4","author":"Zhang","year":"2017","journal-title":"J. Clin. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1395260","DOI":"10.3389\/fcimb.2024.1395260","article-title":"Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"14","author":"Zhang","year":"","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1519906","DOI":"10.3389\/fmicb.2024.1519906","article-title":"An integrative review on the risk factors, prevention, and control strategies for carbapenem-resistant Acinetobacter baumannii colonization in critically ill patients","volume":"15","author":"Zhang","year":"","journal-title":"Front. Microbiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"117","DOI":"10.21037\/atm.2018.09.26","article-title":"A real-world study on adverse drug reactions to Xuebijing injection: hospital intensive monitoring based on 93 hospitals (31,913 cases)","volume":"7","author":"Zheng","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jpba.2017.01.024","article-title":"Rapid determination of 30 bioactive constituents in XueBiJing injection using ultra high performance liquid chromatography-high resolution hybrid quadrupole-orbitrap mass spectrometry coupled with principal component analysis","volume":"137","author":"Zuo","year":"","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e4400","DOI":"10.1002\/bmc.4400","article-title":"Tissue distribution profiles of multiple major bioactive components in rats after intravenous administration of Xuebijing injection by UHPLC-Q-Orbitrap HRMS","volume":"33","author":"Zuo","year":"2019","journal-title":"Biomed. Chromatogr."},{"key":"B63","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jpba.2017.09.010","article-title":"Simultaneous determination and pharmacokinetic study of twelve bioactive compounds in rat plasma after intravenous administration of Xuebijing injection by UHPLC-Q-Orbitrap HRMS","volume":"146","author":"Zuo","year":"","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1598359\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T05:30:05Z","timestamp":1747978205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1598359\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":63,"alternative-id":["10.3389\/fphar.2025.1598359"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1598359","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"article-number":"1598359"}}